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COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer? 
 
The current COVID-19 pandemic caused by SARS-CoV-2 is undoubtedly the biggest and most 
detrimental health crisis the world has ever seen since the 1918 Spanish flu pandemic caused by the 
H1N1 virus. Ever since the first case report back in Dec. 2019, the number of those affected has risen 
to well over 3 million infection cases and well over 200,000 deaths worldwide to date1.  
The last two months (March and April 2020) have witnessed an unsurpassed increase in the number 
of clinical trials worldwide, their aim is to find a solution either in the form of an effective drug(s) to 
eradicate the virus, manage the acute phase of the disease, in particular the complications of the 
‘’Cytokine storm’’, or as prophylaxis i.e. to develop safe and effective vaccines. Clinical trials that are 
sponsored by governments, World Health Organization (WHO), the Big Pharma, with the 
involvement of and in collaboration with universities, charities, hospitals, NGOs and research centres 
worldwide have reached over 1000 trials (recruiting and non-recruiting) according to the National 
Institute of Health database of privately and publicly funded clinical studies conducted around the 
world2. According to the Global Coronavirus COVID-19 Clinical Trial Tracker, there are currently over 
650 trials running worldwide with the majority taking place in China (over 300 trials) followed by the 
USA (over 100 trials)3. 
A search of the recruiting clinical trials reveals a list of old and new drugs that are being 
‘’repurposed’’ where they are tested as potential treatments either for their direct anti-viral activity, 
or for their ability to provide management of selected debilitating respiratory and cardiovascular 
symptoms and complications, characteristic of COVID-19.  
Several relatively new anti-viral drugs including the fixed-dose combination of Lopinavir/Ritonavir, 
Favipiravir, Umifenovir and Remdesivir are being tested either on their own or in combination with 
other measures. Amongst the conventional small (molecular weight of less than 1000 g.mol-1) drug 
molecules tested are the anti-malarial drugs Hydroxychoroquine and Chloroquine, the macrolide 
antibiotic Azithromycin, the angiotensin II receptor antagonist Losartan, the statin Simvastatin, the 
corticosteroids Dexamethasone and Methylprednisolone, vitamins C and D, the anti-parasitic drugs 
Nitazoxanide and Ivermectin (lab-based evidence of anti-viral activity, not yet in clinical trials), the 
anti-gout/anti-micro-tubule agent Colchicine, the NSAIDs Celecoxib, Ibuprofen, Naproxen and 
Tranexamic acid, the acetylcholinesterase inhibitor Pyridostigmine Bromide and the aldosterone 
antagonist and potassium-sparing diuretic Spironolactone.  
Trials involving the use of plasma therapy, stem cells and repurposing biologics including monoclonal 
antibodies such as Sarilumab (rheumatoid arthritis treatment), Tocilizumab (rheumatoid arthritis 
treatment), Siltuximab (multicentric Castleman's disease treatment), Bivacizumab (anti-VEGF 
treatment) are all underway.  
The approach of clinically testing, approving and using registered and investigational drugs for 
clinical applications beyond their original indication (so called repurposing, repositioning or 
retasking) is currently happening at a large and unprecedented scale in an attempt to control the 
COVID-19 pandemic. Such a strategy is likely to give rise to a range of safety and efficacy challenges 
that could be addressed through a pharmaceutical formulation/drug delivery approach. 
Reformulating already approved drugs to overcome issues of instability, poor membrane 
permeability, compromised bioavailability, inadequate duration of action, side effects and 
developing alternative dosage forms to administer via more appropriate routes of administration 
 
 
(e.g. pulmonary instead of oral or oral instead of subcutaneous) are indeed within the realm of 
pharmaceutical formulation and drug development research.  
Development of an effective prophylaxis in the form of a vaccine for COVID-19 is another area of 
research interest where pharmaceutical scientists have already made a difference. mRNA-1273 (in 
Phase 1 trials) is an mRNA-based vaccine formulated by encapsulating the mRNA molecule in lipid 
nanoparticles4. Formulation and development of gene silencing molecules based on RNA 
interference, DNA plasmid, viral vectors, recombinant proteins and new adjuvants, microneedles 
and nanotechnology are areas of active research that could help further advance current knowledge, 
leading to new modalities with better therapeutic outcomes. 
The current COVID-19 pandemic poses a new challenge to pharmaceutical scientists, one that could 
be harnessed and translated to new and exciting research projects leading to novel medicines that 
would make a difference by addressing an unmet, yet urgent clinical need. Despite the global 
lockdown, we are experiencing unprecedented level of collaboration and data sharing amongst 
research communities that is changing the landscape and further facilitating and advancing 
developments. 
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